150 related articles for article (PubMed ID: 28387494)
1. [Optimizing basal insulin therapy in type 2 diabetes].
Scheen AJ; Paquot N
Rev Med Liege; 2017 Mar; 72(3):156-161. PubMed ID: 28387494
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic options for a type 2 diabetic patient not well controlled with metformin plus basal insulin].
Scheen AJ; Paquot N
Rev Med Suisse; 2017 Aug; 13(571):1416-1420. PubMed ID: 28837278
[TBL] [Abstract][Full Text] [Related]
3. [How I manage a patient with type 2 diabetes not well controlled with a metformin plus gliptin combination].
Scheen AJ
Rev Med Liege; 2019 Sep; 74(9):443-450. PubMed ID: 31486312
[TBL] [Abstract][Full Text] [Related]
4. Complementing insulin therapy to achieve glycemic control.
Barnett AH
Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
[TBL] [Abstract][Full Text] [Related]
5. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Guthrie RM
Postgrad Med; 2015 Jun; 127(5):463-79. PubMed ID: 25956345
[TBL] [Abstract][Full Text] [Related]
6. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
Min SH; Yoon JH; Hahn S; Cho YM
Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
[TBL] [Abstract][Full Text] [Related]
7. [About the choice between a DPP-4 inhibitor and a SGLT 2 inhibitor tor treating type 2 diabetes].
Scheen AJ; Paquot N
Rev Med Liege; 2016 Dec; 71(12):579-585. PubMed ID: 28387100
[TBL] [Abstract][Full Text] [Related]
8. [Gliptin-gliflozin combination for treating type 2 diabetes].
Scheen AJ; Paquot N
Rev Med Suisse; 2016 Aug; 12(527):1384-1388. PubMed ID: 28671793
[TBL] [Abstract][Full Text] [Related]
9. DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1407-1417. PubMed ID: 27435042
[TBL] [Abstract][Full Text] [Related]
10. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
Kumar A
Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
[TBL] [Abstract][Full Text] [Related]
11. When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy.
Avogaro A; Delgado E; Lingvay I
Diabetes Metab Res Rev; 2018 May; 34(4):e2981. PubMed ID: 29320602
[TBL] [Abstract][Full Text] [Related]
12. [Rationale supporting basal insulin-incretin combined therapies in type 2 diabetes].
Scheen AJ; Paquot N
Rev Med Liege; 2013 Nov; 68(11):562-8. PubMed ID: 24396969
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy of 'treatment resistant' type 2 diabetes.
Scheen AJ
Expert Opin Pharmacother; 2017 Apr; 18(5):503-515. PubMed ID: 28276972
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
Liu Y; Hong T
Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
[TBL] [Abstract][Full Text] [Related]
15. New forms of insulin and insulin therapies for the treatment of type 2 diabetes.
Cahn A; Miccoli R; Dardano A; Del Prato S
Lancet Diabetes Endocrinol; 2015 Aug; 3(8):638-52. PubMed ID: 26051044
[TBL] [Abstract][Full Text] [Related]
16. [Management of Type 2 Diabetes: a Practical Approach].
Donath M
Praxis (Bern 1994); 2016 Jun; 105(12):699-702. PubMed ID: 27269776
[TBL] [Abstract][Full Text] [Related]
17. [Use of oral glucose-lowering agents in patients with renal impairment].
Scheen AJ; Paquot N
Rev Med Liege; 2017 Oct; 72(10):462-468. PubMed ID: 29058840
[TBL] [Abstract][Full Text] [Related]
18. [Significance of combination therapy with an insulin sensitizer and a DPP-4(dipeptidyl peptidase-4) inhibitor].
Yasuda T; Shimomura I
Nihon Rinsho; 2013 Mar; 71(3):555-62. PubMed ID: 23631252
[TBL] [Abstract][Full Text] [Related]
19. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
Zambrowicz B; Ding ZM; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Smith M; Ruff D; Sands A; Powell D
Clin Ther; 2013 Mar; 35(3):273-285.e7. PubMed ID: 23433601
[TBL] [Abstract][Full Text] [Related]
20. [How I TREAT ... THE ROLE OF DPP-4 INHIBITORS (GLIPTINS) IN THE TREATMENT OF TYPE 2 DIABETES].
Scheen AJ
Rev Med Liege; 2015 Dec; 70(12):593-9. PubMed ID: 26867302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
